$ORCL

Price Prediction: As AI Backlog Soars, Oracle Set for 50% Upside

Oracle (ORCL) trades at $147.17, down 51.46% over a year, despite a $664 billion AI backlog and 121% cloud growth. Analysts set a $214.69 target, implying 50% upside, citing strong backlog conversion potential. Risks include negative free cash flow and high capex guidance.

Original reporting
Published Sep 17, 2026, 6:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 6:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Price Prediction: As AI Backlog Soars, Oracle Set for 50% Upside — source image
Decision brief

The 30-second read

$ORCLNeutralMed
01

Why it matters

The earnings beat and aggressive guidance could drive short‑term buying, but capex and cash‑flow concerns may limit upside.

02

Market read

Oracle's results provide a litmus test for AI‑focused cloud investments and may influence valuation multiples in the sector.

03

What to watch

Potential equity raise beyond the $20B ATM program could dilute shareholders.

Relevance 8/10Novelty 8/10Timing: post‑earnings release

Background

Oracle's AI backlog of $664B and 121% cloud growth are unprecedented in enterprise software.

Company-level read

Ticker impact

$ORCLNeutralMedium confidence
Context

Oracle reported fiscal Q1 2027 revenue of $19.345B, 29.6% YoY growth, and a 121% cloud increase, while guiding FY27 capex of $90‑$95B.

Expected impact

Potential 10‑15% upside if capex is managed; downside risk if cash flow remains negative.

Evidence & confidence

The earnings beat supports the bullish price target, but the large capex and negative free cash flow could pressure the stock.

Market effects

Highlights AI‑driven cloud growth potential for enterprise software sector.

U.S. tech stocks may see volatility as investors weigh earnings versus capex.

Sets a benchmark for AI backlog valuations across global cloud providers.

Counterpoint

If Oracle cannot convert RPO to cash quickly, the stock may underperform despite the price target.

Key entities

  • Larry Ellison

    CEO who highlighted AI backlog and capex plans.

  • Hilary Maxson

    CFO who described projects as cash‑flow positive once ramped.

Related articles

$ORCLMedAI 8/10

Forget Oracle's Stock Price Swings. Its Backlog

Oracle (NYSE: ORCL) reported a $664B backlog, with $300B from OpenAI contracts. Despite a 28% YTD stock decline, the company expects 34% revenue growth and 19% earnings growth. The backlog is 9.2x its trailing 12-month sales, indicating strong future demand for AI cloud services, though OpenAI concentration poses risks.

$ORCLHighAI 8/10

Oracle’s 2026 Cratering: This Pro Is Sure It Will Nearly Triple in the Next 12 Months

Oracle (ORCL) shares fell 11.39% in a week and 25.8% year-to-date despite Q1 FY27 earnings beating estimates. Revenue grew 29.61% to $19.345 billion, cloud infrastructure revenue surged 121%, and remaining performance obligations reached $664 billion. Concerns include high capital expenditure and negative free cash flow. Analysts maintain an average price target of $239, with some targeting $400. Management raised FY27 revenue guidance to at least $90 billion and $8.10 in non-GAAP EPS.

$IBMMedAI 8/10

Quantum Computing News: IBM Gets $1B Award as IONQ Taps Nvidia AI

IBM's Anderon received a $1B U.S. award for quantum wafer R&D, with IBM investing another $1B. IQM Quantum Computers signed a deal for its first South American quantum computer. IonQ and Nvidia tested generative AI for quantum optimization. D-Wave plans to showcase its annealing and gate-model systems. Oracle added post-quantum cryptography to Java 27.

$ORCLHighAI 8/10

Monday's Stock to Watch: Oracle, Blue Owl, and Apollo

Oracle (ORCL) announced an additional $700M restructuring charge due to layoffs, potentially impacting its stock. Blue Owl (OWL) saw a 10.81% drop in stock value, closing at $10.56, amid loan write-down concerns. Apollo (APO) is in talks to acquire J&J’s (JNJ) orthopedics unit, with mixed performance in the medical devices sector.

$ORCLHighAI 8/10

Larry Ellison cancels plan to sell up to $7.5bn of Oracle stock

Larry Ellison, Oracle's Executive Chair, canceled a plan to sell up to $7.5bn of Oracle (NYSE: ORCL) stock, according to the company. The plan, covering 50 million shares, was announced on 22 June 2026 and canceled on 12 September 2026. Oracle reported Q1 2026 revenue of $19.345bn, up from $14.926bn a year earlier, with net income rising to $4.76bn from $2.927bn. The company's cloud infrastructure unit grew 121% year-on-year to $7.4bn.